Volmar Keith E, Idowu Michael O, Souers Rhona J, Nakhleh Raouf E
From the Department of Pathology, Rex Pathology Associates, Raleigh, North Carolina (Dr Volmar); the Department of Pathology, Virginia Commonwealth University, Richmond (Dr Idowu); the Department of Biostatistics, College of American Pathologists, Northfield, Illinois (Ms Souers); and the Department of Pathology, Mayo Clinic Jacksonville, Jacksonville, Florida (Dr Nakhleh).
Arch Pathol Lab Med. 2015 Sep;139(9):1115-24. doi: 10.5858/arpa.2014-0513-CP.
The appropriate and timely performance of molecular testing in anatomic pathology is an indicator of quality. The National Comprehensive Cancer Network (NCCN) publishes a comprehensive treatment guideline that includes recommendations for ancillary testing.
To establish benchmarks for rates of adherence to NCCN testing recommendations through a multi-institutional study.
Participants in a 2013 Q-Probes study of the College of American Pathologists reported data from molecular testing on anatomic pathology cases, excluding hematolymphoid neoplasms, breast primary carcinomas, and gynecologic cytology.
Twenty-six institutions reported data from 2230 molecular testing events. In a retrospective study limited to colon, lung, and melanoma, there was strict adherence to guidelines in a median 71% (10th to 90th percentile range, 33%-90%) and there was at least loose adherence in a median 95% (10th to 90th percentile range, 57%-100%). There was adequate tissue to complete testing in a median 98% (10th to 90th percentile range, 86%-100%); in aggregate the adequacy rate for cell blocks was lower (84%, P < .001). Median test turnaround time was 8 days (10th to 90th percentile range, 4-13 days). In a prospective collection of all organ sites, there was strict adherence to guidelines in a median 53% (10th to 90th percentile range, 20%-71%), and there was at least loose adherence in a median 94% (10th to 90th percentile range, 75%-100%). Adherence to guidelines was higher for lung specimens and in institutions with more multidisciplinary conferences.
This multi-institutional study provides benchmarking data on appropriateness and timeliness of molecular testing in anatomic pathology.
在解剖病理学中适时且恰当地开展分子检测是质量的一项指标。美国国立综合癌症网络(NCCN)发布了一份全面的治疗指南,其中包括辅助检测的建议。
通过一项多机构研究为遵循NCCN检测建议的比率确立基准。
2013年美国病理学家学会Q-Probes研究的参与者报告了解剖病理学病例分子检测的数据,不包括血液淋巴系统肿瘤、乳腺原发性癌和妇科细胞学。
26家机构报告了2230次分子检测事件的数据。在一项限于结肠癌、肺癌和黑色素瘤的回顾性研究中,严格遵循指南的比例中位数为71%(第10百分位数至第90百分位数范围,33%-90%),至少宽松遵循指南的比例中位数为95%(第10百分位数至第90百分位数范围,57%-100%)。有足够组织完成检测的比例中位数为98%(第10百分位数至第90百分位数范围,86%-100%);总体而言,细胞块的充足率较低(84%,P < 0.001)。检测周转时间中位数为8天(第10百分位数至第90百分位数范围,4-13天)。在对所有器官部位的前瞻性数据收集中,严格遵循指南的比例中位数为53%(第10百分位数至第90百分位数范围,20%-71%),至少宽松遵循指南的比例中位数为94%(第10百分位数至第i90百分位数范围,75%-100%)。肺标本遵循指南的情况更好,在多学科会议更多的机构中也是如此。
这项多机构研究提供了关于解剖病理学中分子检测的适宜性和及时性的基准数据。